Selective Estrogen Receptor Modulators and Cardiovascular Events
نویسندگان
چکیده
منابع مشابه
Selective estrogen receptor modulators and cardiovascular events.
ost of the previous observational studies suggest that estrogen replacement therapy reduces cardiovascular risks,1 but meta-analysis of randomized clinical trials showed increased risk of hormone replacement therapy for cardiovascular events.2 Both hypercoagulability and upregulation of inflammation-sensitive proteins could underline the increased risk of estrogen treatment in coronary artery d...
متن کاملSelective Estrogen Receptor Modulators
Selective estrogen receptor modulators (SERMs) are now being used as a treatment for breast cancer, osteoporosis and postmenopausal symptoms, as these drugs have features that can act as an estrogen agonist and an antagonist, depending on the target tissue. After tamoxifen, raloxifene, lasofoxifene and bazedoxifene SERMs have been developed and used for treatment. The clinically decisive differ...
متن کاملSelective estrogen receptor modulators (SERMS).
Hormone receptors and, specifically, estrogen receptors were described about four decades ago. For estrogens, there are two receptors, estrogen receptor alpha (ERalpha) and estrogen receptor beta (ERbeta). The two receptors are coded by different genes and their tissue expression varies across organs. ERalpha is predominantly expressed in reproductive tissues (uterus, breast, ovaries) liver and...
متن کاملSelective estrogen receptor modulators and phytoestrogens.
Scientific achievements in the last two decades have revolutionized the treatment and prevention of breast cancer. This is mainly because of targeted therapies and a better understanding of the relationship between estrogen, its receptor, and breast cancer. One of these discoveries is the use of synthetic selective estrogen modulators (SERMs) such as tamoxifen in the treatment strategy for estr...
متن کاملFocus on cardiovascular health: hormone replacement therapy, estrogen replacement therapy, and selective estrogen receptor modulators.
Walsh • Focus on cardiovascular health C disease is the leading cause of death in the United States today. Fully 52% of women will die of cardiovascular disease, far exceeding the percentage who will die of all cancers combined, and far in excess of the 4% who will die of breast cancer.1 It has been known since the initial findings of the Framingham Study, however, that women have a 20-year adv...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Circulation Journal
سال: 2014
ISSN: 1346-9843,1347-4820
DOI: 10.1253/circj.cj-13-1396